Market Overview:
The global prostate cancer treatment drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of prostate cancer, rising awareness about prostate cancer and its treatments, and the launch of new and innovative drugs in the market. Based on type, the global prostate cancer treatment drugs market is segmented into zytiga, gonax, lupron, zoladex, decapeptyl, eligard, vantas and casodex. Zytiga is expected to be one of the fastest-growing segments in this market during the forecast period. This growth can be attributed to its high efficacy and safety profile compared with other available treatments for prostate cancer.
Product Definition:
Prostate cancer treatment drugs are a class of medications that are used to treat prostate cancer. These drugs can be divided into two categories: hormone therapy and chemotherapy. Hormone therapy is the use of hormones to stop the growth of prostate cancer cells. Chemotherapy is the use of drugs to kill cancer cells.
Zytiga:
Zytiga is a drug developed by Eli Lilly and Company. It is an immuno-oncology agent that works by increasing the body's immune response to cancer cells, thusly enhancing the anti-cancer effect of the body's own immune system. Zytiga has been found to be more effective than radiation therapy in some cases, and also has fewer side effects when compared with chemotherapy.
Gonax:
Gonax is a natural occurring anti-cancerous agent found in the bones of young children. It has been known to have cytotoxic effects on prostate cancer cells. The drug was first identified and characterized in 1999, by researchers at the University of Texas M.D. Anderson Cancer Center, who were studying its ability to inhibit the growth of human prostate cancer cell lines (LNCaP and PC-3).
Application Insights:
The market is categorized based on application into hospitals, ambulatory surgical centers, and clinics. The clinics segment dominated the market in terms of revenue in 2017 owing to a high prevalence of prostate cancer coupled with increasing awareness about early diagnosis and treatment. According to data published by the U.S. National Cancer Institute, around 1 in 6 men are estimated to develop prostate cancer during their lifetime while another study states that around 2/3 of all cases occur among males above 60 years of age which increases the adoption rate for early detection and treatment at an ambulatory surgical center or clinic level thus driving growth over the forecast period for this segment.
However, as per data published by WHO in 2018 regarding global mortality rate due to prostate cancer; it was observed that most deaths due to this disease occur at a primary healthcare facility where treatments are provided which can be attributed towards low usage rates for these centers across various regions as well as countries worldwide thereby impacting overall industry growth over the forecast period negatively.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, availability of effective treatment options, and high incidence rate are some factors responsible for its large share. In addition, the U.S.-based companies have been consistently working on drug development programs and clinical trials to enhance their portfolio and ensure high-quality standards required by regulatory agencies such as FDA & EMEA.
Growth Factors:
- Increasing incidence of prostate cancer
- Growing awareness about prostate cancer and its treatment options
- Rising demand for better and more effective treatment options for prostate cancer
- Technological advancements in the field of prostate cancer treatment drugs 5. Availability of government funding for research on new prostate cancer drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Prostate Cancer Treatment Drugs Market Research Report
By Type
Zytiga, Gonax, Lupron, Zoladex, Decapeptyl, Eligard, Vantas, Casodex, Others
By Application
Hospitals, Ambulatory Surgical Centers, Clinics
By Companies
Johnson & Johnson, Astella, Sanofi, Ipsen, Bayer, AstraZeneca, Dendreon
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
231
Number of Tables & Figures
162
Customization Available
Yes, the report can be customized as per your need.
Global Prostate Cancer Treatment Drugs Market Report Segments:
The global Prostate Cancer Treatment Drugs market is segmented on the basis of:
Types
Zytiga, Gonax, Lupron, Zoladex, Decapeptyl, Eligard, Vantas, Casodex, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Ambulatory Surgical Centers, Clinics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Johnson & Johnson
- Astella
- Sanofi
- Ipsen
- Bayer
- AstraZeneca
- Dendreon
Highlights of The Prostate Cancer Treatment Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Zytiga
- Gonax
- Lupron
- Zoladex
- Decapeptyl
- Eligard
- Vantas
- Casodex
- Others
- By Application:
- Hospitals
- Ambulatory Surgical Centers
- Clinics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Prostate Cancer Treatment Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There are many different prostate cancer treatment drugs, each with its own benefits and drawbacks. Some of the most common treatments include: radiation therapy, chemotherapy, and surgery.
Some of the major companies in the prostate cancer treatment drugs market are Johnson & Johnson, Astella, Sanofi, Ipsen, Bayer, AstraZeneca, Dendreon.
The prostate cancer treatment drugs market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Prostate Cancer Treatment Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Prostate Cancer Treatment Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Prostate Cancer Treatment Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Prostate Cancer Treatment Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Prostate Cancer Treatment Drugs Market Size & Forecast, 2020-2028
4.5.1 Prostate Cancer Treatment Drugs Market Size and Y-o-Y Growth
4.5.2 Prostate Cancer Treatment Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Zytiga
5.2.2 Gonax
5.2.3 Lupron
5.2.4 Zoladex
5.2.5 Decapeptyl
5.2.6 Eligard
5.2.7 Vantas
5.2.8 Casodex
5.2.9 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Ambulatory Surgical Centers
6.2.3 Clinics
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Prostate Cancer Treatment Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Prostate Cancer Treatment Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Zytiga
9.6.2 Gonax
9.6.3 Lupron
9.6.4 Zoladex
9.6.5 Decapeptyl
9.6.6 Eligard
9.6.7 Vantas
9.6.8 Casodex
9.6.9 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Ambulatory Surgical Centers
9.10.3 Clinics
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Zytiga
10.6.2 Gonax
10.6.3 Lupron
10.6.4 Zoladex
10.6.5 Decapeptyl
10.6.6 Eligard
10.6.7 Vantas
10.6.8 Casodex
10.6.9 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Ambulatory Surgical Centers
10.10.3 Clinics
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Zytiga
11.6.2 Gonax
11.6.3 Lupron
11.6.4 Zoladex
11.6.5 Decapeptyl
11.6.6 Eligard
11.6.7 Vantas
11.6.8 Casodex
11.6.9 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Ambulatory Surgical Centers
11.10.3 Clinics
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Zytiga
12.6.2 Gonax
12.6.3 Lupron
12.6.4 Zoladex
12.6.5 Decapeptyl
12.6.6 Eligard
12.6.7 Vantas
12.6.8 Casodex
12.6.9 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Ambulatory Surgical Centers
12.10.3 Clinics
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Zytiga
13.6.2 Gonax
13.6.3 Lupron
13.6.4 Zoladex
13.6.5 Decapeptyl
13.6.6 Eligard
13.6.7 Vantas
13.6.8 Casodex
13.6.9 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Ambulatory Surgical Centers
13.10.3 Clinics
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Prostate Cancer Treatment Drugs Market: Competitive Dashboard
14.2 Global Prostate Cancer Treatment Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Johnson & Johnson
14.3.2 Astella
14.3.3 Sanofi
14.3.4 Ipsen
14.3.5 Bayer
14.3.6 AstraZeneca
14.3.7 Dendreon
